REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gene Security Network (GSN) announced today that it has initiated enrollment for a prospective randomized trial in collaboration with Ferring Pharmaceuticals to evaluate the impact of GSN’s advanced preimplantation genetic diagnosis (PGD) with Parental Support™ on pregnancy and implantation rates in IVF. “IPSO”, or – “Impact of Parental Support on pregnancy Outcomes”, is a multicenter U.S. trial designed to evaluate the potential of GSN’s PGD technology to increase in vitro fertilization (IVF) success. This study is the first multicenter trial to evaluate the efficacy of next generation microarray PGD.
